Nonlinear Dynamics Says It Won t Renew 2D Gel Software OEM Deal with Amersham | GenomeWeb

NEW YORK, July 18 - Nonlinear Dynamics announced today that it has decided not to renew its OEM agreement to supply Amersham Biosciences' proteomics group with 2D gel analysis software.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.